Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock

被引:62
|
作者
Hohn, Andreas [1 ]
Schroeder, Stefan [2 ]
Gehrt, Anna [3 ]
Bernhardt, Kathrin [3 ]
Bein, Berthold [4 ]
Wegscheider, Karl [5 ]
Hochreiter, Marcel [6 ]
机构
[1] Ruhr Univ Bochum, BG Univ Hosp Bergmannsheil, Dept Anaesthesiol Intens Care Palliat Care & Pain, D-44789 Bochum, Germany
[2] Hosp Duren Gem GmbH, Dept Anaesthesiol Intens Care Med & Pain Therapy, D-52351 Duren, Germany
[3] West Coast Hosp, Dept Anesthesiol & Intens Care Med, D-25746 Heide, Germany
[4] Univ Hosp Schleswig Holstein, Dept Anesthesiol & Intens Care Med, D-24105 Kiel, Germany
[5] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, D-20246 Hamburg, Germany
[6] Univ Heidelberg Hosp, Dept Anesthesiol, D-69120 Heidelberg, Germany
关键词
Procalcitonin; Sepsis; Economical outcomes; Intensive care; RESPIRATORY-TRACT INFECTIONS; VENTILATOR-ASSOCIATED PNEUMONIA; INTENSIVE-CARE PATIENTS; ANTIMICROBIAL RESISTANCE; DISEASES-SOCIETY; CONTROLLED-TRIAL; DURATION; GUIDELINES; EPIDEMIOLOGY; INITIATION;
D O I
10.1186/1471-2334-13-158
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Procalcitonin (PCT)-protocols to guide antibiotic treatment in severe infections are known to be effective. But less is known about the long-term effects of such protocols on antibiotic consumption under real life conditions. This retrospective study analyses the effects on antibiotic use in patients with severe sepsis and septic shock after implementation of a PCT-protocol. Methods: We conducted a retrospective ICU-database search for adult patients between 2005 and 2009 with sepsis and organ dysfunction who where treated accordingly to a PCT-guided algorithm as follows: Daily measurements of PCT (BRAHMS PCT LIA (R); BRAHMS Aktiengesellschaft, Hennigsdorf, Germany). Antibiotic therapy was discontinued if 1) clinical signs and symptoms of infection improved and PCT decreased to <= 1 ng/ml, or 2) if the PCT value was >1 ng/ml, but had dropped to 25-35% of the initial value within three days. The primary outcome parameters were: antibiotic days on ICU, ICU re-infection rate, 28-day mortality rate, length of stay (LOS) in ICU, mean antibiotic costs (per patient) and ventilation hours. Data from 141 patients were included in our study. Primary outcome parameters were analysed using covariance analyses (ANCOVA) to control for effects by gender, age, SAPS II, APACHE II and effective cost weight. Results: From baseline data of 2005, duration of antibiotic therapy was reduced by an average of 1.0 day per year from 14.3 +/- 1.2 to 9.0 +/- 1.7 days in 2009 (p=0.02). ICU re-infection rate was decreased by yearly 35.1% (95% CI -53 to -8.5; p=0.014) just as ventilation hours by 42 hours per year (95% CI -72.6 to -11.4; p=0.008). ICU-LOS was reduced by 2.7 days per year (p<0.001). Trends towards an average yearly reduction of 28-day mortality by -22.4% (95% CI -44.3 to 8.1; p=0.133) and mean cost for antibiotic therapy/patient by -14.3 Euro (95% CI -55.7 to 27.1) did not reach statistical significance. Conclusions: In a real-life clinical setting, implementation of a PCT-protocol was associated with a reduced duration of antibiotic therapy in septic ICU patients without compromising clinical or economical outcomes.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] VALIDATION OF THE ELECSYS BRAHMS PROCALCITONIN ASSAY IN PATIENTS WITH SEVERE SEPSIS OR SEPTIC SHOCK
    Handy, Beverly
    Jones, Prentiss
    Ostlund, Richard, Jr.
    Schuetz, Philipp
    Schwabe, Andrej
    Johannes, Sascha
    Sherman, Jingzi
    Shapiro, Nathan
    CRITICAL CARE MEDICINE, 2016, 44 (12)
  • [42] Procalcitonin Trend Predicts Discharge to Home in Severe Sepsis and Septic Shock Patients
    Kramer, N.
    Amico, K.
    Leon, L.
    Rosario, J.
    Dub, L.
    Lebowitz, D.
    Ballinger, B.
    Ganti, L.
    ANNALS OF EMERGENCY MEDICINE, 2017, 70 (04) : S14 - S14
  • [43] Procalcitonin is not associated with positive blood culture in patients with severe sepsis and septic shock
    Prucha, M.
    Zazula, R.
    Hyanek, T.
    Moravec, M.
    INFECTION, 2015, 43 : S42 - S43
  • [44] Procalcitonin-Guided Treatment on Duration of Antibiotic Therapy and Cost in Septic Patients (PRODA): a Multi-Center Randomized Controlled Trial
    Jeon, Kyeongman
    Suh, Jae Kyung
    Jang, Eun Jin
    Cho, Songhee
    Ryu, Ho Geol
    Na, Sungwon
    Hong, Sang-Bum
    Lee, Hyun Joo
    Kim, Jae Yeol
    Lee, Sang-Min
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2019, 34 (14)
  • [45] A new diagnostic and severity marker in patients with SIRS, sepsis, severe sepsis and septic shock; procalcitonin
    S Çelebi
    P Ergin Özcan
    S Tugrul
    N Çakar
    F Esen
    Critical Care, 4 (Suppl 1):
  • [46] Do we need new trials of procalcitonin-guided antibiotic therapy?
    Lisboa, Thiago
    Salluh, Jorge
    Povoa, Pedro
    CRITICAL CARE, 2018, 22
  • [47] Do we need new trials of procalcitonin-guided antibiotic therapy?
    Thiago Lisboa
    Jorge Salluh
    Pedro Povoa
    Critical Care, 22
  • [48] Procalcitonin-guided antibiotic therapy: A systematic review and meta-analysis
    Soni, Nilam J.
    Samson, David J.
    Galaydick, Jodi L.
    Vats, Vikrant
    Huang, Elbert S.
    Aronson, Naomi
    Pitrak, David L.
    JOURNAL OF HOSPITAL MEDICINE, 2013, 8 (09) : 530 - 540
  • [49] Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations
    Tokman, Sofya
    Schuetz, Philipp
    Bent, Stephen
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2011, 9 (06) : 727 - 735
  • [50] Procalcitonin kinetics as a prognostic marker in severe sepsis/septic shock
    Poddar, Banani
    Gurjar, Mohan
    Singh, Sushma
    Aggarwal, Amita
    Singh, Ratender
    Azim, Afzal
    Baronia, Arvind
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2015, 19 (03) : 140 - 146